Evidence map›Paper›PMID 41278398›Full record

ArticleJTO clinical and research reports2025

Crizotinib in Patients With

Lorenza Landi, Rita Chiari, Marcello Tiseo, Giulio Metro, Filippo de Marinis, Angelo Delmonte, Silvia Novello, Diego Luigi Cortinovis, Domenico Galetta, Laura Bonanno and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Lorenza LandiClinical Trials Unit: Phase 1 and Precision Medicine, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Rita ChiariUOC Oncologia AST PU, Pesaro, Italy.
Marcello TiseoDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Giulio MetroAzienda Ospedaliera di Perugia, Perugia, Italy.
Filippo de MarinisIRCCS Istituto Europeo di Oncologia, Milano, Italy.
Angelo DelmonteIRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori," Meldola (FC), Italy.
Silvia NovelloDipartimento di Oncologia, Università di Torino, AOU San Luigi Gonzaga, Orbassano, Italy.
Diego Luigi CortinovisMedical Oncology Fondazione, IRCCS San Gerardo dei Tintori, Monza, Italy.
Domenico GalettaIRCCS Istituto Tumori "Giovanni Paolo II," Bari, Italy.
Laura BonannoDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
Cesare GridelliDivision of Medical Oncology, S.G. Moscati Hospital, Avellino, Italy.
Alessandro MorabitoOncologia Clinica Sperimentale Toraco-Polmonare, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy.
Francesco GrossiDepartment of Medicine and Technological Innovation, Università degli Studi dell'Insubria, Varese, Italy.
Andrea TorchiaMedical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Diana GiannarelliFondazione Policlinico Universitario A. Gemelli, IRCCS, Roma, Italy.
Gloria BorraA.O.U. "Maggiore della Carità," Novara, Italy.
Francesca MazzoniOncology Department, Careggi University Hospital, Firenze, Italy.
Sara PilottoSection of Oncology, Department of Engineering for Innovation Medicine (DIMI), University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy.
Federico CappuzzoMedical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Crizotinib, the first approved targeted therapy for Methods: This post hoc analysis of the METROS study assessed survival outcomes in patients with Results: Among 64 patients with Conclusion: This analysis supports the efficacy of crizotinib in patients with advanced NSCLC and

Indexed as

Brain metastasesCrizotinibNon-small-cell lung cancerPost hoc analysis

Identifiers

PMID41278398
PMCPMC12639264

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.